NEODECADRON
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NEODECADRON (NEODECADRON).
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. Dexamethasone is a potent corticosteroid with glucocorticoid and mineralocorticoid activity that binds to the glucocorticoid receptor, modulating gene expression to suppress inflammation and immune responses.
| Metabolism | Neomycin is minimally absorbed after topical application; absorbed fraction is primarily excreted unchanged by the kidneys. Dexamethasone is metabolized in the liver via CYP3A4 to inactive metabolites. |
| Excretion | Renal: ~70% as unchanged drug and metabolites; fecal/biliary: ~30% |
| Half-life | Terminal elimination half-life: 3-4 hours for neomycin; 6-8 hours for dexamethasone. Clinical context: Neomycin accumulates with renal impairment; dexamethasone has prolonged effects in hepatic dysfunction. |
| Protein binding | Dexamethasone: ~77% bound to albumin; neomycin: negligible binding (<10%) |
| Volume of Distribution | Dexamethasone: 0.5-0.8 L/kg (large Vd indicates extensive tissue distribution); neomycin: 0.2-0.3 L/kg (low Vd due to hydrophilicity) |
| Bioavailability | Oral: neomycin 1-3% (largely unabsorbed); dexamethasone 70-80%. IM dexamethasone: 80-100%; ophthalmic: minimal systemic absorption |
| Onset of Action | Ophthalmic solution: minutes to hours; topical: hours; IM dexamethasone: 1-2 hours |
| Duration of Action | Ophthalmic: 4-6 hours; topical: 6-12 hours; IM dexamethasone: 12-36 hours |
1-2 drops into conjunctival sac every 1-2 hours during the day and every 2-4 hours at night for severe conditions; for mild conditions, 1-2 drops 4-6 times daily. Ophthalmic suspension.
| Dosage form | OINTMENT |
| Renal impairment | No dose adjustment required for topical ophthalmic use; systemic absorption negligible. |
| Liver impairment | No dose adjustment required for topical ophthalmic use; systemic absorption negligible. |
| Pediatric use | Not recommended for pediatric use due to potential systemic effects; safety and efficacy not established. |
| Geriatric use | Use with caution due to increased risk of intraocular pressure elevation and cataract formation; monitor intraocular pressure regularly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NEODECADRON (NEODECADRON).
| Breastfeeding | Corticosteroids excreted in breast milk; M/P ratio not specifically reported for neomycin/dexamethasone. Use with caution; monitor infant for growth suppression and adrenal suppression. |
| Teratogenic Risk | Category C: Corticosteroids cross placenta. First trimester: Increased risk of cleft palate (OR 1.3-3.4). Second/third trimester: Fetal adrenal suppression, intrauterine growth restriction, oligohydramnios with prolonged use. |
| Fetal Monitoring |
■ FDA Black Box Warning
None (FDA label does not include a black box warning). However, aminoglycosides carry risks of nephrotoxicity and ototoxicity with systemic absorption.
| Serious Effects |
Hypersensitivity to neomycin, dexamethasone, or any component of the formulation. Untreated viral, fungal, or tubercular infections of the skin or eye. Perforated tympanic membrane (for otic preparations).
| Precautions | Prolonged use may lead to suppression of adrenal function, cataracts, glaucoma, or secondary infections including fungal overgrowth. Neomycin may cause hypersensitivity reactions including contact dermatitis. Systemic absorption may occur with extensive application, especially on broken skin, leading to nephrotoxicity and ototoxicity. Use with caution in patients with renal impairment. |
Loading safety data…
| Monitor maternal blood pressure, blood glucose, fluid/electrolytes. Fetal ultrasound for growth restriction, amniotic fluid volume, and adrenal suppression signs. |
| Fertility Effects | No direct evidence of fertility impairment; high-dose corticosteroids may suppress hypothalamic-pituitary-adrenal axis, potentially affecting ovulation. |